文献速递炎症性肠病

高体重指数与生物制剂治疗的溃疡性结肠炎患者治疗失败和手术风险增加相关

High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2018-04-17

这项单中心回顾性队列研究纳入2011-2016年160例接受生物制剂治疗的溃疡性结肠炎患者,按基线体重指数评估治疗反应。多因素分析显示,体重指数每增加1 kg/m2,治疗失败风险增加4%(aHR 1.04,95%CI 1.00-1.08),手术/住院风险增加8%(aHR 1.08,95%CI 1.02-1.14)。结论认为体重指数与治疗失败风险独立相关,且不受给药方案影响。

要点

  • 体重指数每增加1 kg/m2,治疗失败风险增加4%(aHR 1.04,95%CI 1.00-1.08)。
  • 体重指数每增加1 kg/m2,手术/住院风险增加8%(aHR 1.08,95%CI 1.02-1.14)。
  • 体重指数对治疗失败的影响在按体重给药和固定剂量方案中均可见。

核心结论

  • 体重指数与接受生物制剂治疗的溃疡性结肠炎患者治疗失败风险独立相关,且不受给药方案影响。

研究设计与样本

  • 单中心回顾性队列研究,纳入2011-2016年接受生物制剂治疗的溃疡性结肠炎患者160例(50%男性,55%使用英夫利西单抗),中位(IQR)年龄36岁(26-52),体重指数24.3 kg/m2(21.4-28.7)。

主要发现

  • 多因素分析显示,体重指数每增加1 kg/m2,治疗失败风险增加4%(aHR 1.04,95%CI 1.00-1.08)。
  • 体重指数每增加1 kg/m2,手术/住院风险增加8%(aHR 1.08,95%CI 1.02-1.14)。
  • 体重指数对治疗失败的影响在按体重给药方案或固定剂量治疗的患者中均可见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity's impact on clinical outcomes in biologic-treated patients with ulcerative colitis (UC) is inconsistent. AIM: To evaluate the impact of obesity on real world response to biological therapy in patients with UC. METHODS: In a single-centre retrospective cohort study between 2011-2016 of biologic-treated patients with UC, we evaluated treatment response by baseline body mass index (BMI). Primary outcome was treatment failure (composite outcome of IBD-related surgery/hospitalisation or treatment modification including dose escalation, treatment discontinuation or addition of corticosteroids); secondary outcomes were risk of IBD-related surgery/hospitalisation and endoscopic remission. We conducted multivariate Cox proportional hazard analyses to evaluate the independent impact of BMI on clinical outcomes. Stratified analysis by weight-based regimens (infliximab) or fixed-dose regimens (adalimumab, golimumab, vedolizumab, certolizumab pegol) was performed. RESULTS: We included 160 biologic-treated UC patients (50% males, 55% on infliximab) with median (IQR) age 36 y (26-52) and BMI 24.3 kg/m2 (21.4-28.7). On multivariate analysis, each 1 kg/m2 increase in BMI was associated with 4% increase in the risk of treatment failure (adjusted hazard ratio [aHR], 1.04 [95% CI, 1.00-1.08]) and 8% increase in the risk of surgery/hospitalisation (aHR, 1.08 [1.02-1.14]). The effect on treatment failure was seen in patients on weight-based dosing regimens or fixed-dose therapies. CONCLUSION: BMI is independently associated with increased risk of treatment failure in biologic-treated patients with UC, independent of dosing regimen.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kurnool S, Nguyen NH, Proudfoot J, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018. PMID: 29665045. doi:10.1111/apt.14665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。